Research Analysts Set Expectations for A Q3 Earnings

Agilent Technologies, Inc. (NYSE:A) – Analysts at Leerink Partnrs boosted their Q3 2025 earnings per share estimates for Agilent Technologies in a research report issued on Wednesday, December 18th. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings of $1.42 per share for the quarter, up from their previous forecast of $1.41. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.56 per share. Leerink Partnrs also issued estimates for Agilent Technologies’ Q1 2026 earnings at $1.49 EPS, Q2 2026 earnings at $1.43 EPS, Q3 2026 earnings at $1.52 EPS and Q4 2026 earnings at $1.66 EPS.

A number of other research firms have also recently commented on A. Sanford C. Bernstein dropped their price target on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating for the company in a research note on Tuesday, November 26th. Bank of America cut their target price on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Citigroup raised their price target on Agilent Technologies to $165.00 and gave the stock a “buy” rating in a research note on Thursday, December 19th. JPMorgan Chase & Co. cut their price objective on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 26th. Finally, Evercore ISI lifted their target price on Agilent Technologies from $135.00 to $145.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Agilent Technologies presently has an average rating of “Hold” and an average target price of $143.62.

Agilent Technologies Stock Up 1.1 %

Shares of NYSE A opened at $136.10 on Monday. The stock has a market capitalization of $39.11 billion, a price-to-earnings ratio of 30.79, a P/E/G ratio of 4.48 and a beta of 1.07. Agilent Technologies has a 12-month low of $124.16 and a 12-month high of $155.35. The company has a current ratio of 2.09, a quick ratio of 1.58 and a debt-to-equity ratio of 0.57. The firm’s 50-day moving average price is $135.66 and its 200-day moving average price is $136.51.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Monday, November 25th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.41 by $0.05. The business had revenue of $1.70 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. The company’s revenue was up .8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.38 EPS.

Agilent Technologies Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 22nd. Investors of record on Tuesday, December 31st will be paid a $0.248 dividend. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.24. This represents a $0.99 annualized dividend and a dividend yield of 0.73%. The ex-dividend date of this dividend is Tuesday, December 31st. Agilent Technologies’s payout ratio is currently 22.40%.

Insider Buying and Selling

In other news, SVP Dominique Grau sold 9,990 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the sale, the senior vice president now directly owns 40,011 shares in the company, valued at $5,801,595. The trade was a 19.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.33% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James Trust N.A. grew its holdings in shares of Agilent Technologies by 2.7% during the second quarter. Raymond James Trust N.A. now owns 4,837 shares of the medical research company’s stock worth $627,000 after buying an additional 126 shares in the last quarter. Bailard Inc. grew its stake in Agilent Technologies by 4.4% during the 2nd quarter. Bailard Inc. now owns 2,613 shares of the medical research company’s stock valued at $339,000 after acquiring an additional 111 shares in the last quarter. First Command Advisory Services Inc. acquired a new stake in Agilent Technologies in the 2nd quarter valued at about $47,000. State of Michigan Retirement System lifted its stake in Agilent Technologies by 1.2% in the 2nd quarter. State of Michigan Retirement System now owns 84,181 shares of the medical research company’s stock worth $10,912,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Agilent Technologies by 1.1% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 13,298 shares of the medical research company’s stock worth $1,724,000 after purchasing an additional 148 shares during the last quarter. 87.42% of the stock is owned by hedge funds and other institutional investors.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.